Transcript Slide 1
“Here we go again” Implications for SHA’s when implementing BASHH GC guidelines
Martin Murchie Senior Sexual Health Adviser www.sandyford.org
www.sandyford.org
Aim of today
• Discuss how Sandyford implemented BASHH GC guidelines • What it meant for the Sexual Health Adviser team • Audit outcome
www.sandyford.org
What's Abba got to do with it?
• Gonorrhea here we go again, • My my how can I resist you • Gonorrhoea does it show again!
• My my just how much I’ve missed you?
www.sandyford.org
A wee bit of history….
• A much misunderstood infection!
• Early writings in Egypt, China & Japan • Even in the Bible “unclean discharge” • First isolated in 1879 by Albert Neisser • Originally called Micrococcus but later named Gonoccocus.
www.sandyford.org
Early Treatments
• Variety of treatments in the beginning – Urethral lavage / Mercury
www.sandyford.org
Early Treatments
• The magic bullet 1900s • Known as Salvarsan – Unstable in air – Also used for syphilis
www.sandyford.org
Treatments1940’s
• Good old penicillin • Poor old penicillin – Resistance in 1960’s/1970’s
www.sandyford.org
Today
• Range of antibiotics have been used.
• Real issue with increasing resistance • Some cases of “Superbug” multi-resistant GC strains found • BASHH Guideline – UK National Guidelines for the Management of Gonorrhoea in adults – June 2011
www.sandyford.org
Recommendations
• Nucleic Acid Amplification tests (NAATs) can be used for both anogential and pharyngeal specimens. Supplementary testing is required for reactive tests from low prevalence populations and for specimens from the rectum or pharynx.
• First-line treatment is now Cefitriaxone 500 mg IM stat plus Azithromycin 1g stat.
• Test of cure is recommended for all cases.
www.sandyford.org
Sandyford response
• NAATs already in place.
• Culture if NAAT positive also in place • Treatment change from Cefixime to Cefitriaxone along with Azithromax (unless sensitivities available) • SHA team diaried all clients with GC for a 3 week test of cure, with 2 recall attempts.
www.sandyford.org
GC – May 2011
• 82 cases of GC found (this includes cultures) – 23 cases of Throat GC – 8 cases of Rectal GC – 15 cases of Urethral GC – 10 cases if Cervical GC • 46 clients in total (20% had GC in more than one site).
• Sensitivities for 16 (35%) of the clients (19% resistant to Cipro – 3 clients).
www.sandyford.org
15% 2% 4% 7%
Treatment
Treatment Given
72% Cefitriaxone with Azith Cefitriaxone Ciproxin Azithromycine Untreated
www.sandyford.org
Who attended for a test of cure?
• 18 clients attended as arranged
42%
• • 1 st – recall - 25 recalled
36%
attended.
• 2 nd – recall
29%
–14 recalled attended
72%
all.
attended over – 42% due to SHA recall
50 45 40 35 30 25 20 15 10 5 0 25 18 14 9 4 0 N o R e c a 1 ll s t R e c a ll 2 n d R e c a ll 46 31 T o ta l A tte n d e d Recall Attended www.sandyford.org
What about PN?
• All 43 clients had partner notification carried out. 100% • 88 contacts in total – only 48% traceable • 56% of contacts attended – though only 26% verified outcomes.
48% 15, 30% 13, 26%
Total Number of Contacts PN outcomes
22, 44% 52% Untraceable Traceable.
No Outcome Contacts attended Hard Contacts attended soft
www.sandyford.org
Summary
• Change of guidelines manageable with SHA input.
• 72% of clients returned who had SHA contact – Time consuming – PN outcomes disappointing • Big question IS IT WORTH IT?
www.sandyford.org
www.sandyford.org
The future…..
• Researchers have found that the bacteria Neisseiria gonnorhoea, which causes the unfortunate malady, gonorrhoea, has, at some point in the history of its existence, picked up part of the human genome. As yet, the extraneous DNA appears to serve no useful function and stands merely as an interesting monument to the lengthy relationship between our two species .
www.sandyford.org